Evidence Hub

Ashwagandha as an Evidence-Based Adaptogen: Bridging Clinical and Preclinical Insights for Stress and Anxiety Management

Pawan Lekurware, Suchitra G Shrikhande, Deepak Jaiswal

International journal of Ayurvedic medicine, 2026

650 participants

Abstract

Background: Withania somnifera (L.) Dunal (Ashwagandha) is an Ayurvedic Rasayana traditionally used for stress and anxiety. Clinical trials report symptomatic benefits, while preclinical studies suggest mechanisms including HPA-axis modulation and anti-inflammatory effects. Objective: To systematically compare clinical efficacy, safety, and mechanistic preclinical evidence for Ashwagandha in stress and anxiety. Methods: We searched PubMed, Scopus, Web of Science, Cochrane CENTRAL, Clinical Trial Registry of India and Google Scholar (first 200 results) from database inception to [insert last search date] for randomized controlled trials (RCTs) and preclinical studies assessing Ashwagandha’s anxiolytic or anti-stress effects. Two reviewers independently screened studies and extracted data following PRISMA 2020. Risk of bias was assessed using Cochrane RoB 2.0 (clinical) and SYRCLE (preclinical). Where outcomes were sufficiently homogenous we planned pooled analyses; otherwise we present a qualitative synthesis. Full search strings are provided in Supplementary File 1. Results: Nine RCTs (≈650 participants) and 12 preclinical studies met inclusion criteria. RCTs reported consistent reductions in perceived stress and anxiety scores and decreased serum cortisol; adverse events were mild and infrequent. Preclinical studies demonstrated HPA-axis attenuation (↓ACTH/corticosterone), enhanced GABAergic signalling, reduced proinflammatory cytokines (IL-6, TNF-α), increased BDNF, and…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free